Federal award (DEFINITIVE CONTRACT, fiscal year 2021)
Recipient: MOLECULAR EXPRESS, INC
Awarding agency: Department of Health and Human Services / National Institutes of Health
Funding agency: Department of Health and Human Services / National Institutes of Health
Period of performance: 2020-06-01 to 2022-07-31
Current total value of award: $299993
Description: THE OBJECTIVE OF THIS CONTRACT IS TO DEVELOP A VESIVAX PLATFORM-BASED LIPOSOMAL FORMULATION THAT WILL EFFICIENTLY DISPLAY THE HIV IMMUNOGEN.